Optical Express Group claims good patient outcomes

Article

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better.

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better. The business has also recently made a $12 million investment installing iFS 150 femtosecond laser systems in all its 44 treatment clinics in the UK.

Commenting on the trend towards better than 20/20 outcomes Dr Steve Schallhorn, Medical Director and Chair of the International Medical Advisory Board for Optical Express said: “What we have reported is that our highly skilled surgeons using the very latest advancements in LASIK technology, consistently results in most patients achieving better than 20/20 unaided vision. These outcomes are phenomenal and testament to the medical and surgical care provided by Optical Express. It is also setting a new world-wide standard for laser eye surgery procedure outcomes.

“From a very early stage, Optical Express decided to lead from the front by advancing the frontiers of laser eye surgery. Together with the greatest experience in ophthalmology, our International Medical Advisory Board is second to none and is driving up standards to deliver safe and effective eye surgery with high levels of patient satisfaction.

“We continue to have very high levels of satisfaction among our patients. This is evidenced through our growth over the last year, during a time of deep economic turmoil.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.